Korean trial tests supercharged immune cells against deadly brain tumor
NCT ID NCT00807027
Summary
This study tested whether adding a special immune cell therapy (Immuncell-LC) to standard chemotherapy (temozolomide) could better control a fast-growing brain cancer called glioblastoma. It involved 180 adults in Korea who were newly diagnosed and had recent surgery. Researchers compared how long patients lived without their cancer getting worse between those who received the cell therapy and those who only got chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gyunghee University Medical Center
Seoul, South Korea
-
Hanyang University Guri Hospital
Guri-si, Gyeonggi-do, South Korea
-
Konkuk University
Seoul, South Korea
-
Korea University Anam Hospital
Seoul, South Korea
-
Samsung Seoul Medical Center
Seoul, South Korea
-
Seoul Asan Medical Center
Seoul, South Korea
-
Yeonsei University Medical Center
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.